Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorKırık, Ali
dc.contributor.authorDoğru, Teoman
dc.contributor.authorKeyik, Bahar Yanik
dc.contributor.authorŞen, Hacer
dc.contributor.authorEroğlu, Mustafa
dc.contributor.authorBaykan, Özgür
dc.contributor.authorBozyel, Emel Aslan
dc.contributor.authorErgene, Ayşe
dc.contributor.authorSelçuk, Eda
dc.contributor.authorTaşçı, İlker
dc.contributor.authorSönmez, Yusuf Alper
dc.date.accessioned2024-06-04T10:52:44Z
dc.date.available2024-06-04T10:52:44Z
dc.date.issued2023en_US
dc.identifier.issn1128-3602
dc.identifier.urihttps://doi.org/10.26355/eurrev_202309_33567
dc.identifier.urihttps://hdl.handle.net/20.500.12462/14787
dc.descriptionKırık, Ali (Balikesir Author)en_US
dc.description.abstractOBJECTIVE: Mitochondrial open reading frame of the 12s ribosomal RNA type-c (MOTS-c) is a novel identified mitochondrial signal transmission peptide that plays an important role in glucose, amino acid and lipid metabolism. In this study, we aimed to investigate the relationship of circulating MOTS-c level with noninvasive scores of fibrosis and the components of metabolic syndrome (MetS) in patients with metabolic dysfunction-associated fatty liver disease (MAFLD). PATIENTS AND METHODS: This was a single-center cross-sectional study, and the participants were divided into two groups based on their liver ultrasound results: the fatty liver group and the healthy control group. The MOTS-c level was measured by the ELISA method. Non-alcoholic fatty liver disease fibrosis score (NFS) and fibrosis 4 (FIB-4) were used to determine the level of liver fibrosis. Statistical analyses were performed using Statistical Package for Social Science 15.0 package program. RESULTS: One hundred fifty patients (male, n=57) with MAFLD [median age 41.0 (14) years] and 84 healthy controls (male, n=34) [median age 36.0 (22) years] were included in this study. Patients with MAFLD had significantly lower MOTS-c levels than the healthy controls (p=0.009). The MOTS-c level was significantly lower in subjects with MetS (n=48) compared to those without MetS (n=186) (p=0.01). In the total population (n=234), MOTS-c levels negatively correlated with the presence of MAFLD, NFS, FIB-4, and components of MetS. CONCLUSIONS: Individuals diagnosed with MetS and MAFLD tend to have lower levels of MOTS-c. Additionally, these lower levels are inversely correlated with both the components of MetS and noninvasive fibrosis scores. MAFLD negatively correlated to the MetS components and noninvasive scores of fibrosis.en_US
dc.language.isoengen_US
dc.publisherVerduci Publisheren_US
dc.relation.isversionof10.26355/eurrev_202309_33567en_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectLiver Fibrosisen_US
dc.subjectMAFLDen_US
dc.subjectMetabolic Syndromeen_US
dc.subjectMOTS-cen_US
dc.titleThe relationship of circulating MOTS-c level with liver fibrosis and metabolic components in patients with metabolic dysfunction-associated fatty liver diseaseen_US
dc.typearticleen_US
dc.relation.journalEuropean Review for Medical and Pharmacological Sciencesen_US
dc.contributor.departmentTıp Fakültesien_US
dc.contributor.authorID0000-0002-7982-9262en_US
dc.contributor.authorID0000-0002-7982-9262en_US
dc.contributor.authorID0000-0003-3358-7330en_US
dc.contributor.authorID0000-0002-9290-6285en_US
dc.contributor.authorID0000-0002-7526-7151en_US
dc.contributor.authorID0000-0001-8551-6900en_US
dc.contributor.authorID0000-0000-2644-3503en_US
dc.contributor.authorID0000-0002-0936-2476en_US
dc.identifier.volume27en_US
dc.identifier.issue17en_US
dc.identifier.startpage8074en_US
dc.identifier.endpage8080en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster

info:eu-repo/semantics/embargoedAccess
Aksi belirtilmediği sürece bu öğenin lisansı: info:eu-repo/semantics/embargoedAccess